ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,048.42
      -0.46%
      US Tech 100
      17,154.40
      1.04%
      Dow Jones
      38,085.80
      -0.98%
      Brent Oil
      88.13
      -0.02%
      Bitcoin
      64,400.31
      -0.13%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. RAPT Therapeutics Inc (RAPT)

      7. RAPT Therapeutics Inc (RAPT) News

      RAPT

      RAPT Therapeutics (RAPT)

      RAPT Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RAPT
      DateTimeSourceHeadlineSymbolCompany
      12:52PMiHub NewswireFeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
      04/09/202412:00PMGlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
      03/07/20244:15PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
      03/07/20248:08AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
      03/07/20248:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
      03/07/20248:00AMGlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
      03/05/20244:30PMGlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
      02/22/20245:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
      02/20/20244:29PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
      02/20/20247:30AMGlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
      02/14/20248:52AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
      02/13/20248:00AMGlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
      01/31/20248:00AMGlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
      01/02/20248:00AMGlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
      11/27/20238:00AMGlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
      11/13/20238:08AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
      11/13/20238:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
      11/13/20238:00AMGlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
      11/03/202312:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
      11/03/202312:00PMGlobeNewswire Inc.RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCNASDAQ:RAPTRAPT Therapeutics Inc
      11/01/20234:05PMGlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in NovemberNASDAQ:RAPTRAPT Therapeutics Inc
      10/23/20234:40PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RAPTRAPT Therapeutics Inc
      10/18/20239:00AMGlobeNewswire Inc.RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
      08/30/20234:05PMGlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in SeptemberNASDAQ:RAPTRAPT Therapeutics Inc
      08/18/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RAPTRAPT Therapeutics Inc
      08/11/20234:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
      08/11/20238:57AMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RAPTRAPT Therapeutics Inc
      08/11/20238:10AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
      08/11/20238:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
      08/11/20238:00AMGlobeNewswire Inc.RAPT Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:RAPT